Paclitaxel impairs adipose stem cell proliferation and differentiation

Rachel Choron, Shaohua Chang, Sophia Khan, Miguel A. Villalobos, Ping Zhang, Jeffrey P. Carpenter, Thomas N. Tulenko, Yuan Liu

Research output: Contribution to journalArticle

Abstract

Background Cancer patients with chemotherapy-induced immunosuppression have poor surgical site wound healing. Prior literature supports the use of human adipose-derived stem cell (hASC) lipoinjection to improve wound healing. It has been established that multipotent hASCs facilitate neovascularization, accelerate epithelialization, and quicken wound closure in animal models. Although hASC wound therapy may benefit surgical cancer patients, the chemotherapeutic effects on hASCs are unknown. We hypothesized that paclitaxel, a chemotherapeutic agent, impairs hASC growth, multipotency, and induces apoptosis. Methods hASCs were isolated and harvested from consented, chemotherapy and radiation naive patients. Growth curves, MTT (3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide), and EdU (5-ethynyl-2-deoxyguridine) assays measured cytotoxicity and proliferation. Oil Red O stain, Alizarin Red stain, matrigel tube formation assay, and quantitative polymerase chain reaction analyzed hASC differentiation. Annexin V assay measured apoptosis. Immunostaining and Western blot determined tumor necrosis factor α (TNF-α) expression. Results hASCs were selectively more sensitive to paclitaxel (0.01-30 μM) than fibroblasts (P < 0.05). After 12 d, paclitaxel caused hASC growth arrest, whereas control hASCs proliferated (P = 0.006). Paclitaxel caused an 80.6% reduction in new DNA synthesis (P < 0.001). Paclitaxel severely inhibited endothelial differentiation and capillary-like tube formation. Differentiation markers, lipoprotein lipase (adipogenic), alkaline phosphatase (osteogenic), CD31, and van Willebrand factor (endothelial), were significantly decreased (all P < 0.05) confirming paclitaxel impaired differentiation. Paclitaxel was also found to induce apoptosis and TNF-α was upregulated in paclitaxel-treated hASCs (P < 0.001). Conclusions Paclitaxel is more cytotoxic to hASCs than fibroblasts. Paclitaxel inhibits hASC proliferation, differentiation, and induces apoptosis, possibly through the TNF-α pathway. Paclitaxel's severe inhibition of endothelial differentiation indicates neovascularization disruption, possibly causing poor wound healing in cancer patients receiving chemotherapy.

Original languageEnglish (US)
Pages (from-to)404-415
Number of pages12
JournalJournal of Surgical Research
Volume196
Issue number2
DOIs
StatePublished - Jun 15 2015
Externally publishedYes

Fingerprint

Paclitaxel
Cell Differentiation
Stem Cells
Cell Proliferation
Wound Healing
Apoptosis
Tumor Necrosis Factor-alpha
Drug Therapy
Coloring Agents
Growth
Fibroblasts
Re-Epithelialization
Neoplasms
Lipoprotein Lipase
Annexin A5
Differentiation Antigens
Cell- and Tissue-Based Therapy
Immunosuppression
Alkaline Phosphatase
Animal Models

Keywords

  • Cancer therapy
  • Chronic wounds
  • Human adipose-derived stem cells
  • Neovascularization
  • Paclitaxel
  • Wound healing

ASJC Scopus subject areas

  • Surgery

Cite this

Choron, R., Chang, S., Khan, S., Villalobos, M. A., Zhang, P., Carpenter, J. P., ... Liu, Y. (2015). Paclitaxel impairs adipose stem cell proliferation and differentiation. Journal of Surgical Research, 196(2), 404-415. https://doi.org/10.1016/j.jss.2015.03.026

Paclitaxel impairs adipose stem cell proliferation and differentiation. / Choron, Rachel; Chang, Shaohua; Khan, Sophia; Villalobos, Miguel A.; Zhang, Ping; Carpenter, Jeffrey P.; Tulenko, Thomas N.; Liu, Yuan.

In: Journal of Surgical Research, Vol. 196, No. 2, 15.06.2015, p. 404-415.

Research output: Contribution to journalArticle

Choron, R, Chang, S, Khan, S, Villalobos, MA, Zhang, P, Carpenter, JP, Tulenko, TN & Liu, Y 2015, 'Paclitaxel impairs adipose stem cell proliferation and differentiation', Journal of Surgical Research, vol. 196, no. 2, pp. 404-415. https://doi.org/10.1016/j.jss.2015.03.026
Choron, Rachel ; Chang, Shaohua ; Khan, Sophia ; Villalobos, Miguel A. ; Zhang, Ping ; Carpenter, Jeffrey P. ; Tulenko, Thomas N. ; Liu, Yuan. / Paclitaxel impairs adipose stem cell proliferation and differentiation. In: Journal of Surgical Research. 2015 ; Vol. 196, No. 2. pp. 404-415.
@article{bbb1dc976fef4877a0e666627c57911c,
title = "Paclitaxel impairs adipose stem cell proliferation and differentiation",
abstract = "Background Cancer patients with chemotherapy-induced immunosuppression have poor surgical site wound healing. Prior literature supports the use of human adipose-derived stem cell (hASC) lipoinjection to improve wound healing. It has been established that multipotent hASCs facilitate neovascularization, accelerate epithelialization, and quicken wound closure in animal models. Although hASC wound therapy may benefit surgical cancer patients, the chemotherapeutic effects on hASCs are unknown. We hypothesized that paclitaxel, a chemotherapeutic agent, impairs hASC growth, multipotency, and induces apoptosis. Methods hASCs were isolated and harvested from consented, chemotherapy and radiation naive patients. Growth curves, MTT (3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide), and EdU (5-ethynyl-2-deoxyguridine) assays measured cytotoxicity and proliferation. Oil Red O stain, Alizarin Red stain, matrigel tube formation assay, and quantitative polymerase chain reaction analyzed hASC differentiation. Annexin V assay measured apoptosis. Immunostaining and Western blot determined tumor necrosis factor α (TNF-α) expression. Results hASCs were selectively more sensitive to paclitaxel (0.01-30 μM) than fibroblasts (P < 0.05). After 12 d, paclitaxel caused hASC growth arrest, whereas control hASCs proliferated (P = 0.006). Paclitaxel caused an 80.6{\%} reduction in new DNA synthesis (P < 0.001). Paclitaxel severely inhibited endothelial differentiation and capillary-like tube formation. Differentiation markers, lipoprotein lipase (adipogenic), alkaline phosphatase (osteogenic), CD31, and van Willebrand factor (endothelial), were significantly decreased (all P < 0.05) confirming paclitaxel impaired differentiation. Paclitaxel was also found to induce apoptosis and TNF-α was upregulated in paclitaxel-treated hASCs (P < 0.001). Conclusions Paclitaxel is more cytotoxic to hASCs than fibroblasts. Paclitaxel inhibits hASC proliferation, differentiation, and induces apoptosis, possibly through the TNF-α pathway. Paclitaxel's severe inhibition of endothelial differentiation indicates neovascularization disruption, possibly causing poor wound healing in cancer patients receiving chemotherapy.",
keywords = "Cancer therapy, Chronic wounds, Human adipose-derived stem cells, Neovascularization, Paclitaxel, Wound healing",
author = "Rachel Choron and Shaohua Chang and Sophia Khan and Villalobos, {Miguel A.} and Ping Zhang and Carpenter, {Jeffrey P.} and Tulenko, {Thomas N.} and Yuan Liu",
year = "2015",
month = "6",
day = "15",
doi = "10.1016/j.jss.2015.03.026",
language = "English (US)",
volume = "196",
pages = "404--415",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Paclitaxel impairs adipose stem cell proliferation and differentiation

AU - Choron, Rachel

AU - Chang, Shaohua

AU - Khan, Sophia

AU - Villalobos, Miguel A.

AU - Zhang, Ping

AU - Carpenter, Jeffrey P.

AU - Tulenko, Thomas N.

AU - Liu, Yuan

PY - 2015/6/15

Y1 - 2015/6/15

N2 - Background Cancer patients with chemotherapy-induced immunosuppression have poor surgical site wound healing. Prior literature supports the use of human adipose-derived stem cell (hASC) lipoinjection to improve wound healing. It has been established that multipotent hASCs facilitate neovascularization, accelerate epithelialization, and quicken wound closure in animal models. Although hASC wound therapy may benefit surgical cancer patients, the chemotherapeutic effects on hASCs are unknown. We hypothesized that paclitaxel, a chemotherapeutic agent, impairs hASC growth, multipotency, and induces apoptosis. Methods hASCs were isolated and harvested from consented, chemotherapy and radiation naive patients. Growth curves, MTT (3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide), and EdU (5-ethynyl-2-deoxyguridine) assays measured cytotoxicity and proliferation. Oil Red O stain, Alizarin Red stain, matrigel tube formation assay, and quantitative polymerase chain reaction analyzed hASC differentiation. Annexin V assay measured apoptosis. Immunostaining and Western blot determined tumor necrosis factor α (TNF-α) expression. Results hASCs were selectively more sensitive to paclitaxel (0.01-30 μM) than fibroblasts (P < 0.05). After 12 d, paclitaxel caused hASC growth arrest, whereas control hASCs proliferated (P = 0.006). Paclitaxel caused an 80.6% reduction in new DNA synthesis (P < 0.001). Paclitaxel severely inhibited endothelial differentiation and capillary-like tube formation. Differentiation markers, lipoprotein lipase (adipogenic), alkaline phosphatase (osteogenic), CD31, and van Willebrand factor (endothelial), were significantly decreased (all P < 0.05) confirming paclitaxel impaired differentiation. Paclitaxel was also found to induce apoptosis and TNF-α was upregulated in paclitaxel-treated hASCs (P < 0.001). Conclusions Paclitaxel is more cytotoxic to hASCs than fibroblasts. Paclitaxel inhibits hASC proliferation, differentiation, and induces apoptosis, possibly through the TNF-α pathway. Paclitaxel's severe inhibition of endothelial differentiation indicates neovascularization disruption, possibly causing poor wound healing in cancer patients receiving chemotherapy.

AB - Background Cancer patients with chemotherapy-induced immunosuppression have poor surgical site wound healing. Prior literature supports the use of human adipose-derived stem cell (hASC) lipoinjection to improve wound healing. It has been established that multipotent hASCs facilitate neovascularization, accelerate epithelialization, and quicken wound closure in animal models. Although hASC wound therapy may benefit surgical cancer patients, the chemotherapeutic effects on hASCs are unknown. We hypothesized that paclitaxel, a chemotherapeutic agent, impairs hASC growth, multipotency, and induces apoptosis. Methods hASCs were isolated and harvested from consented, chemotherapy and radiation naive patients. Growth curves, MTT (3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide), and EdU (5-ethynyl-2-deoxyguridine) assays measured cytotoxicity and proliferation. Oil Red O stain, Alizarin Red stain, matrigel tube formation assay, and quantitative polymerase chain reaction analyzed hASC differentiation. Annexin V assay measured apoptosis. Immunostaining and Western blot determined tumor necrosis factor α (TNF-α) expression. Results hASCs were selectively more sensitive to paclitaxel (0.01-30 μM) than fibroblasts (P < 0.05). After 12 d, paclitaxel caused hASC growth arrest, whereas control hASCs proliferated (P = 0.006). Paclitaxel caused an 80.6% reduction in new DNA synthesis (P < 0.001). Paclitaxel severely inhibited endothelial differentiation and capillary-like tube formation. Differentiation markers, lipoprotein lipase (adipogenic), alkaline phosphatase (osteogenic), CD31, and van Willebrand factor (endothelial), were significantly decreased (all P < 0.05) confirming paclitaxel impaired differentiation. Paclitaxel was also found to induce apoptosis and TNF-α was upregulated in paclitaxel-treated hASCs (P < 0.001). Conclusions Paclitaxel is more cytotoxic to hASCs than fibroblasts. Paclitaxel inhibits hASC proliferation, differentiation, and induces apoptosis, possibly through the TNF-α pathway. Paclitaxel's severe inhibition of endothelial differentiation indicates neovascularization disruption, possibly causing poor wound healing in cancer patients receiving chemotherapy.

KW - Cancer therapy

KW - Chronic wounds

KW - Human adipose-derived stem cells

KW - Neovascularization

KW - Paclitaxel

KW - Wound healing

UR - http://www.scopus.com/inward/record.url?scp=84930384277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930384277&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2015.03.026

DO - 10.1016/j.jss.2015.03.026

M3 - Article

C2 - 25891676

AN - SCOPUS:84930384277

VL - 196

SP - 404

EP - 415

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -